Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service
Joint offering enables acceleration of genomic panel design for translational and clinical disease research SOUTH SAN FRANCISCO, Calif., June 07, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation announced today that it has entered into a co-marketing agreement with Genomenon to offer evidence-based genomic panel design services for translational and clinical disease research. The rapidly expanding knowledge base of genes and... Read more